Delayed Function of Renal Transplant Clinical Trial
Official title:
Effects of the Use of "de Novo" Everolimus for the Expression of Cytokines in Kidneys From Extended Criteria Donors and With Delayed Graft Function
This is an open, randomized, single-center study. The selected patients will be first
divided into two major groups according to the type of organ to be transplanted: standard
criteria donor (SCD) or extended criteria (ECD) kidney. Then, each group will be randomly
allocated to one of the treatments: tacrolimus (TAC) or everolimus (EVL).
All patients received induction therapy with basiliximab (BXB) and maintenance with
Mycophenolate Sodium (MYF) and prednisone (P). This study will evaluate as Primary
objectives: To characterize the molecular profile of cytokines in kidneys obtained from
deceased donors such as "standard" (SCD) and extended criteria (ECD) in biopsies taken
before and after transplantation and to evaluate the effect of treatment with everolimus
(EVL) in the expression of these molecules. And as Secondaries objectives: To correlate the
pattern of cytokines with delayed graft function (DGF), cold ischemia time, episodes of
acute rejection and patient and graft survival.
A total of 80 patients will participate in the study, being distributed into 4 groups of 20
individuals. In a pilot study to assess the interventional effect of the mmediate use of EVL
on the cytokine profile of ECD and SCD kidneys, compared to conventional immunosuppressive
therapy with TAC, no statistical power analysis could be performed a priori.
Definitions of Extended Criteria Donor and Delayed Graft Function (DGF) Deceased donors aged
≥ 60 years or aged between 50 and 59 years and with at least two of the following risk
factors: history of systemic hypertension terminal creatinine levels > 1.5 mg/dL or death by
a cerebrovascular accident.
DGF (delayed graft function) is defined as the need for dialysis in the first 7 days after
transplantation.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02658162 -
A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients
|
Phase 2 | |
Recruiting |
NCT01513707 -
The Effects of Pre-transplant Dialysis Modality on Post-transplant Events
|
N/A | |
Recruiting |
NCT02621281 -
Clinical Impact of Hypothermic Machine Perfusion in Renal Transplant Recipients
|
N/A | |
Terminated |
NCT01403389 -
A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant
|
Phase 2 | |
Completed |
NCT02490202 -
Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant
|
Phase 2/Phase 3 |